Managing Established Patients: Switching, Adherence, Spontaneous Remission, and Treatment Duration

For patients currently well-controlled on omalizumab or dupilumab, routine therapeutic switching is not indicated and may introduce unnecessary disruption to a successful regimen. The clinical rationale for switching or adding remibrutinib is strongest in patients experiencing breakthrough disease where BTK inhibition offers a mechanistically distinct intervention. The availability of 3 step-up agents also creates a practical bridging opportunity: remibrutinib's rapid onset makes it well-suited for patients experiencing a flare while pursuing prior authorization for a long-term biologic. For new patients, presenting all 3 options with a clear explanation of their respective profiles supports genuine shared decision-making without defaulting to a prescribing hierarchy that the evidence does not support.

Adherence to a twice-daily oral regimen presents a real-world challenge distinct from the adherence profile of injectable biologics. Patients managed with injections typically have adherence supported by clinic-based or pharmacy-based administration schedules; oral agents depend entirely on patient behavior. This is compounded by a disease-specific dynamic: patients who achieve rapid symptom control on remibrutinib may question the need for continued therapy precisely because the treatment has worked. Clinicians should proactively address this at initiation, counseling patients that symptom improvement does not signal that therapy is no longer necessary and that premature discontinuation will likely result in recurrence. A structured re-evaluation at 6 to 12 months of complete control is a reasonable framework for discussing a monitored discontinuation attempt in appropriate patients.

In this video segment, Nicole Chase, MD, and Jason Hawkes, MD, examine spontaneous remission as the key variable underlying discontinuation decisions. Without a validated biomarker to predict its onset, the only practical way to determine whether a patient has remitted is to attempt discontinuation after a defined period of disease control. Chase suggests a minimum of 6 months of sustained control, and ideally 1 year, before considering this step in patients with severe disease, framing the continued treatment period as suppression of the underlying pro-inflammatory state rather than simply symptom management. Both experts agree that patients who discontinue and experience recurrence typically return to therapy quickly, because the memory of symptomatic disease reasserts itself rapidly once hives return — a self-correcting dynamic that reduces the clinical stakes of a monitored discontinuation attempt while reinforcing the importance of patient education about the likely outcome.